These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34695561)

  • 41. The role of the endocannabinoid system as a therapeutic target for autism spectrum disorder: Lessons from behavioral studies on mouse models.
    Pietropaolo S; Marsicano G
    Neurosci Biobehav Rev; 2022 Jan; 132():664-678. PubMed ID: 34813825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The potential role of oxytocin and perinatal factors in the pathogenesis of autism spectrum disorders - review of the literature.
    Vanya M; Szucs S; Vetro A; Bartfai G
    Psychiatry Res; 2017 Jan; 247():288-290. PubMed ID: 27974283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lurasidone for the treatment of irritability and anger in autism spectrum disorders.
    McClellan L; Dominick KC; Pedapati EV; Wink LK; Erickson CA
    Expert Opin Investig Drugs; 2017 Aug; 26(8):985-989. PubMed ID: 28685626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroimmune Alterations in Autism: A Translational Analysis Focusing on the Animal Model of Autism Induced by Prenatal Exposure to Valproic Acid.
    Deckmann I; Schwingel GB; Fontes-Dutra M; Bambini-Junior V; Gottfried C
    Neuroimmunomodulation; 2018; 25(5-6):285-299. PubMed ID: 30157484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The early overgrowth theory of autism spectrum disorder: Insight into convergent mechanisms from valproic acid exposure and translational models.
    Chen O; Tahmazian I; Ferrara HJ; Hu B; Chomiak T
    Prog Mol Biol Transl Sci; 2020; 173():275-300. PubMed ID: 32711813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Oxytocin in the treatment of the social deficits associated to autism spectrum disorders].
    Cachafeiro-Espino C; Vale-Martínez AM
    Rev Neurol; 2015 Nov; 61(9):421-8. PubMed ID: 26503318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oxytocin attenuates deficits in social interaction but not recognition memory in a prenatal valproic acid-induced mouse model of autism.
    Hara Y; Ago Y; Higuchi M; Hasebe S; Nakazawa T; Hashimoto H; Matsuda T; Takuma K
    Horm Behav; 2017 Nov; 96():130-136. PubMed ID: 28942000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Valproic acid exposure decreases the mRNA stability of Bcl-2 via up-regulating miR-34a in the cerebellum of rat.
    Dai X; Yin Y; Qin L
    Neurosci Lett; 2017 Sep; 657():159-165. PubMed ID: 28803955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Roles of Epigenetics and Glial Cells in Drug-Induced Autism Spectrum Disorder.
    Csoka AB; El Kouhen N; Bennani S; Getachew B; Aschner M; Tizabi Y
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical potential of oxytocin in autism spectrum disorder: current issues and future perspectives.
    Benner S; Yamasue H
    Behav Pharmacol; 2018 Feb; 29(1):1-12. PubMed ID: 28857771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder.
    Madden JM; Lakoma MD; Lynch FL; Rusinak D; Owen-Smith AA; Coleman KJ; Quinn VP; Yau VM; Qian YX; Croen LA
    J Autism Dev Disord; 2017 Jan; 47(1):144-154. PubMed ID: 27817163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oxytocin for the treatment of autism spectrum disorder in children.
    Griffiths JL; Mishaal RA; Nabetani M; Goldman RD
    Can Fam Physician; 2022 Feb; 68(2):103-105. PubMed ID: 35177498
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel mechanisms and treatment approaches in autism spectrum disorder.
    Brian J; Doyle-Thomas K; Baribeau D; Anagnostou E
    Discov Med; 2016 Aug; 22(119):47-54. PubMed ID: 27585230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psychopharmacological interventions in autism spectrum disorder.
    Accordino RE; Kidd C; Politte LC; Henry CA; McDougle CJ
    Expert Opin Pharmacother; 2016; 17(7):937-52. PubMed ID: 26891879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NEXMIF/KIDLIA Knock-out Mouse Demonstrates Autism-Like Behaviors, Memory Deficits, and Impairments in Synapse Formation and Function.
    Gilbert J; O'Connor M; Templet S; Moghaddam M; Di Via Ioschpe A; Sinclair A; Zhu LQ; Xu W; Man HY
    J Neurosci; 2020 Jan; 40(1):237-254. PubMed ID: 31704787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene-environment interaction counterbalances social impairment in mouse models of autism.
    Kim JW; Park K; Kang RJ; Gonzales EL; Oh HA; Seung H; Ko MJ; Cheong JH; Chung C; Shin CY
    Sci Rep; 2019 Aug; 9(1):11490. PubMed ID: 31391512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options.
    Masi A; DeMayo MM; Glozier N; Guastella AJ
    Neurosci Bull; 2017 Apr; 33(2):183-193. PubMed ID: 28213805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current status of biological treatment options in Autism Spectrum Disorder.
    Eapen V; Nicholls L; Spagnol V; Mathew NE
    Asian J Psychiatr; 2017 Dec; 30():1-10. PubMed ID: 28704714
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging mechanisms of valproic acid-induced neurotoxic events in autism and its implications for pharmacological treatment.
    Taleb A; Lin W; Xu X; Zhang G; Zhou QG; Naveed M; Meng F; Fukunaga K; Han F
    Biomed Pharmacother; 2021 May; 137():111322. PubMed ID: 33761592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improvement of autistic-like behaviors in adult rats prenatally exposed to valproic acid through early suppression of NMDA receptor function.
    Mohammadi S; Asadi-Shekaari M; Basiri M; Parvan M; Shabani M; Nozari M
    Psychopharmacology (Berl); 2020 Jan; 237(1):199-208. PubMed ID: 31595334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.